Legend Biotech (LEGN) Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for the Treatment of R/R Multiple Myeloma

Go back to Legend Biotech (LEGN) Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for the Treatment of R/R Multiple Myeloma
(NASDAQ: LEGN) Delayed: 29.60 -1.42 (4.58%)
Previous Close $31.02    52 Week High
Open $31.05    52 Week Low
Day High $32.50    P/E N/A 
Day Low $29.13    EPS
Volume 2,397,891